-
1
-
-
42649096927
-
Trends in kidney transplantation over the past decade
-
DOI 10.2165/00003495-200868001-00002
-
Knoll G. Trends in kidney transplantation over the past decade. Drugs 2008; 68: 3-10 (Pubitemid 351601432)
-
(2008)
Drugs
, vol.68
, Issue.SUPPL. 1
, pp. 3-10
-
-
Knoll, G.1
-
2
-
-
42149136030
-
Biotransformation enzymes and drug transporters pharmacogenetics in relation to immunosuppressive drugs: Impact on pharmacokinetics and clinical outcome
-
Mourad M, Wallemacq P, De Meyer et al. Biotransformation enzymes and drug transporters pharmacogenetics in relation to immunosuppressive drugs: impact on pharmacokinetics and clinical outcome. Transplantation 2008; 85: 19-24
-
(2008)
Transplantation
, vol.85
, pp. 19-24
-
-
Mourad, M.1
Meyer De, W.P.2
-
3
-
-
60849086797
-
Individualization of immunosuppression: Concepts and rationale
-
WavamunnoMD, Chapman JR. Individualization of immunosuppression: concepts and rationale. Curr Opin Organ Transplant 2008; 13: 604-608
-
(2008)
Curr Opin Organ Transplant
, vol.13
, pp. 604-608
-
-
Wavamunno, M.D.1
Chapman, J.R.2
-
4
-
-
34548083672
-
Cytochrome P450 3A polymorphisms and immunosuppressive drugs: An update
-
DOI 10.2217/14622416.8.7.835
-
Anglicheau D, Legendre C, Beaune P et al. Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update. Pharmacogenomics 2007; 8: 835-849 (Pubitemid 47288980)
-
(2007)
Pharmacogenomics
, vol.8
, Issue.7
, pp. 835-849
-
-
Anglicheau, D.1
Legendre, C.L.2
Beaune, P.3
Thervet, E.4
-
5
-
-
33645864935
-
Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro
-
Dai Y, Hebert MF, Isoherranen N et al. Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab Dispos 2006; 34: 836-847
-
(2006)
Drug Metab Dispos
, vol.34
, pp. 836-847
-
-
Dai, Y.1
Hebert, M.F.2
Isoherranen, N.3
-
6
-
-
21444449731
-
ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation
-
DOI 10.1681/ASN.2004100882
-
Hauser IA, Schaeffeler E, Gauer S et al. ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J Am Soc Nephrol 2005; 16: 1501-1511 (Pubitemid 41716536)
-
(2005)
Journal of the American Society of Nephrology
, vol.16
, Issue.5
, pp. 1501-1511
-
-
Hauser, I.A.1
Schaeffeler, E.2
Gauer, S.3
Scheuermann, E.H.4
Wegner, B.5
Gossmann, J.6
Ackermann, H.7
Seidl, C.8
Hocher, B.9
Zanger, U.M.10
Geiger, H.11
Eichelbaum, M.12
Schwab, M.13
-
7
-
-
1542373607
-
Association between ABCB1 (multidrug resistance transporter) genotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitors
-
DOI 10.1097/00008571-200311000-00002
-
Hebert MF, Dowling AL, Gierwatowski C et al. Association between ABCB1 (multidrug resistance transporter) genotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitors. Pharmacogenetics 2003; 13: 661-674 (Pubitemid 38316510)
-
(2003)
Pharmacogenetics
, vol.13
, Issue.11
, pp. 661-674
-
-
Hebert, M.F.1
Dowling, A.L.S.2
Gierwatowski, C.3
Lin, Y.S.4
Edwards, K.L.5
Davis, C.L.6
Marsh, C.L.7
Schuetz, E.G.8
Thummel, K.E.9
-
8
-
-
72049101913
-
Donor age and renal P-glycoprotein expression associate with chronic histological damage in renal allografts
-
Naesens M, Lerut E, de Jonge H et al. Donor age and renal P-glycoprotein expression associate with chronic histological damage in renal allografts. J Am Soc Nephrol 2009; 20: 2468-2480
-
(2009)
J Am Soc Nephrol
, vol.20
, pp. 2468-2480
-
-
Naesens, M.1
Lerut, E.2
De Jonge, H.3
-
9
-
-
25144433260
-
Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability
-
Wang D, Johnson AD, Papp AC et al. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C〉T affects mRNA stability. Pharmacogenet Genomics 2005; 15: 693-704 (Pubitemid 41345321)
-
(2005)
Pharmacogenetics and Genomics
, vol.15
, Issue.10
, pp. 693-704
-
-
Wang, D.1
Johnson, A.D.2
Papp, A.C.3
Kroetz, D.L.4
Sadee, W.5
-
10
-
-
33846504706
-
A "silent" polymorphism in the MDR1 gene changes substrate specificity
-
DOI 10.1126/science.1135308
-
Kimchi-Sarfaty C, Oh JM, KimIW et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 2007; 315: 525-528 (Pubitemid 46175758)
-
(2007)
Science
, vol.315
, Issue.5811
, pp. 525-528
-
-
Kimchi-Sarfaty, C.1
Oh, J.M.2
Kim, I.-W.3
Sauna, Z.E.4
Calcagno, A.M.5
Ambudkar, S.V.6
Gottesman, M.M.7
-
11
-
-
33748710224
-
Multidrug resistance gene-1 (MDR-1) haplotypes have a minor influence on tacrolimus dose requirements
-
DOI 10.1097/01.tp.0000234942.78716.c0, PII 0000789020060915000017
-
Fredericks S, Moreton M, Reboux S et al. Multidrug resistance gene-1 (MDR-1) haplotypes have a minor influence on tacrolimus dose requirements. Transplantation 2006; 82: 705-708 (Pubitemid 44395243)
-
(2006)
Transplantation
, vol.82
, Issue.5
, pp. 705-708
-
-
Fredericks, S.1
Moreton, M.2
Reboux, S.3
Carter, N.D.4
Goldberg, L.5
Holt, D.W.6
MacPhee, I.A.M.7
-
12
-
-
40549112692
-
CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients
-
DOI 10.1097/FPC.0b013e3282f75f88, PII 0121301120080400000007
-
Hesselink DA, van Schaik RH, van Agteren Met al. CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients. Pharmacogenet Genomics 2008; 18: 339-348 (Pubitemid 351367527)
-
(2008)
Pharmacogenetics and Genomics
, vol.18
, Issue.4
, pp. 339-348
-
-
Hesselink, D.A.1
Van Schaik, R.H.N.2
Van Agteren, M.3
De Fijter, J.W.4
Hartmann, A.5
Zeier, M.6
Budde, K.7
Kuypers, D.R.J.8
Pisarski, P.9
Meur, Y.L.10
Mamelok, R.D.11
Van Gelder, T.12
-
13
-
-
77952585319
-
Optimization of initial tacrolimus dose using pharmacogenetic testing
-
Thervet E, Loriot MA, Barbier S et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin Pharmacol Ther 2010; 87: 721-726
-
(2010)
Clin Pharmacol Ther
, vol.87
, pp. 721-726
-
-
Thervet, E.1
Loriot, M.A.2
Barbier, S.3
|